Gut Microbiota (GM) Biodiversity in Patients With Solid Tumors Treated With Immune Checkpoint Inhibitors (ICIs): a Monocenter Prospective Study to Identify the Interactions Between GM and ICIs
Overview
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Enrollment
- 70
- Locations
- 1
- Primary Endpoint
- The difference in alfa and beta diversity of GM in the stool sample
Overview
Brief Summary
Although it is a milestone in the treatment of solid neoplasms, Immunotherapy (ICI) is still burdened by low response rate to the treatment and the occurrence of immune-related adverse events (irAEs). Recently, many studies have suggested that the The diversity of the intestinal microbiota (GM) can modulate response to ICIs [1]. The GM would be able to produce several molecules that can influence the growth of cancer cells and modulate anti-cancer immunity.
Our project aims to investigate changes in the subject and its relationship to immunotherapy.
Dynamic changes in cytokines can be a indicator of increased or decreased toxin translocation bacterial and therefore of the greater or lesser integrity of the barrier intestinal. Define the influence of diet on changes in GM can also help us understand how to modify these factors to improve the outcome of the subject undergoing immunotherapy.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients aged ≥18 years
- •Life-expectancy ≥6 months;
- •All participants have signed the consent form before enrollment
- •Patients with cancer who have to start immunotherapy with or without chemotherapy/targeted therapy
Exclusion Criteria
- •Patients reporting an intake of antibiotic therapy during the last 30 days (rifaximin therapy used in patients with hepatocellular carcinoma in order to decrease the occurrence of overt Hepatic Encephalopathy is permitted) or any probiotic therapy in the last 30 days
- •A personal history of autoimmune or inflammatory bowel disease
- •Any major intestinal surgery (including bariatric surgery) in the previous six months
- •Ongoing enteral or parenteral nutrition
- •Patients with psychiatric illness/social situations that would limit compliance with study requirements.
Outcomes
Primary Outcomes
The difference in alfa and beta diversity of GM in the stool sample
Time Frame: After 3 weeks, after 12 weeks, after 24 weeks and in the case of progression disease
Secondary Outcomes
- The difference in alfa and beta diversity of GM in the stool sample(From time 0, baseline (at the start of ICIs) to the occurrence of irAEs)
- The difference in the cytokine profile in the blood sample(From time 0 baseline (at the start of ICIs) to the different time points (after 3 weeks, after 12 weeks, after 24 weeks and in the case of progression disease))
- The predictive factors associated with response to treatment with ICIs will be measured related to QueMD questionnaire score for adherence to Mediterranean diet at baseline, difference in QueMD questionnaire score from baseline to week 12.(At the end of Cycle 3 or 4 (each cycle is 28 days))
- The predictive factors associated with development of irAEs will be measured related to QueMD questionnaire score at baseline, baseline body composition and sarcopenia diagnosis, and baseline NRS-2002 score(Baseline)
- Difference in body composition from baseline to week 12, related to the difference in alfa and beta diversity of GM in the stool sample from baseline to week 12(From baseline to week 12)
Investigators
Angioletta Lasagna
Oncologist
Fondazione IRCCS Policlinico San Matteo di Pavia